AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06045013
Drug: 5% dextrose injections with methylprednisolone acetate 40 mg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ultrasound-guided injection of 3 ml 5% dextrose with 1 ml 40 mg/ml methylprednisolone acetate in carpal tunnel via ulnar approach.
Trial: NCT05924321
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV infusion of matching placebo
Trial: NCT06531837
Drug: Remifentanil (Target-Controlled Infusion)
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The plasma drug concentrations of remifentanil were set at 0.5 ng/ml, 1 ng/ml, and 1.5 ng/ml. After each plasma drug concentration reached a steady state, the NRS scores were assessed, and resting-state EEG was recorded for at least 5 minutes.
Trial: NCT06531837
Drug: Flurbiprofen (Single intravenous injection)
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single intravenous injection of Flurbiprofen at a dose of 100 mg. Collect resting-state EEG data and NRS scores 10 minutes after administration.
Trial: NCT06326346
Drug: Liporaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liporaxel 200mg/m2 twice daily orally on day 1, 8, and 15 every 4 weeks (1 cycle = 4 weeks)
Trial: NCT05037825
Drug: Checkpoint Inhibitor, Immune
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-PD-1, anti-PD-L1, or anti-CTLA-4 as a single agent or in combination with another checkpoint inhibitor or other treatment agent or modality (e.g., targeted therapy, chemotherapy, surgery, radiation, etc.) in accordance with FDA-labeled use of the agent
Trial: NCT04859452
Drug: Simvastatin tablets
RxNorm normalized name: Simvastatin Tablets
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Simvastatin, tablet, oral
Trial: NCT05310071
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT00000714
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05883124
Drug: Exelon® 9.5 mg/24 h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
Trial: NCT05317312
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet
Trial: NCT06361680
Drug: Coenzyme Q10 Cap/Tab as natural factors capsules or kirkman tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A will take Soft gel capsules or tablets of Coenzyme Q10 in a dose of 100-200mg of natural factors or kirkman but group B will not take Coenzyme Q10 just observe them
Trial: NCT05533619
Drug: Proton pump inhibitor
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatients using proton pump inhibitor
Trial: NCT05807490
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as oral suspensions BID over 14 days
Trial: NCT05807490
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as oral suspensions QD over 14 days
Trial: NCT05807490
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as oral suspensions every 12 hour (BID) or everyday (QD) over 14 days
Trial: NCT05807490
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
Trial: NCT05293119
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone furoate 0.1% ointment once daily
Trial: NCT04617457
Drug: nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: preoperative chemotherapy
Trial: NCT06372210
Drug: Placebo IEM tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo-embedded IEM tablet.
Trial: NCT06372210
Drug: Abilify MyCite®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral aripiprazole-embedded IEM tablet.
Trial: NCT04728802
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill
Trial: NCT05782777
Drug: high-intensity statin monotherapy (atoravastatin 40mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial dose of lipid-lowering therapy will be atoravastatin 40mg. During follow-up, the dose of atoravastatin 40mg is strongly recommended to be maintained.
Trial: NCT06517914
Drug: YH35995
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of YH35995
Trial: NCT06517914
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of Placebo
Trial: NCT00002100
Drug: Curdlan sulfate
RxNorm normalized name: curdlan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05582798
Drug: Alpha 1-Proteinase Inhibitor 180mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha1-proteinase inhibitor (human) intravenous infusion
Trial: NCT05582798
Drug: Alpha 1-Proteinase Inhibitor 120mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha1-proteinase inhibitor (human) intravenous infusion
Trial: NCT05888857
Drug: MEDI5752
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A treatment cycle consists of 3 weeks. MEDI5752 will be administered by intravenous infusion at a fixed dose on Day 1 of each cycle
Trial: NCT00115414
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00115414
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06239727
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Metronomic adjuvant capecitabine chemotherapy: 650 mg/m2 p.o. bid, 1 year, adminstration starts immediately after concurrent chemoradiotherapy.
Trial: NCT05192239
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially available non-THC fruit snack
Trial: NCT05138861
Drug: TP-03 (Lotilaner Ophthalmic Solution), 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single drop of the ophthalmic solution will be instilled in each eye on the morning of Day 1 and then twice a day (in the morning and in the evening, approximately 12 hours apart) starting on Day 2 for 40 consecutive days (Days 2 to 41). Thereafter, a single drop of the ophthalmic solution will be instilled in each eye on the morning of Day 42, for a total of 82 consecutive doses administered in each eye.
Trial: NCT04564092
Drug: DaTSCAN™ Ioflupane (123I) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will receive a single administration of DaTSCAN™ ioflupane (123I) injection by bolus IV injection with a nominal iodine (123I) activity of 111 MBq ±10%, in a maximum volume of 5 mL.
Trial: NCT05344495
Drug: hyalase group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 15 mg 0.5% plus 2 mL normal saline containing 300 international units (IU) hyaluronidase.
Trial: NCT05702983
Drug: STSA-1002 subcutaneous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single low dose on day 1 following protocol requirements.
Trial: NCT05702983
Drug: STSA-1002 subcutaneous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single high dose on day 1 following protocol requirements.
Trial: NCT05839314
Drug: Huaier granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huaier granule, oral administration, 10g each time, 3 times a day, continuous medication for 24 weeks. After 24 weeks of treatment, the dosage should be adjusted according to efficacy.
Trial: NCT05839314
Drug: Ciclosporin soft capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial dose of Ciclosporin soft capsules is an oral dose of 3.5mg/kg/d, divided into two equal doses, given every 12 hours. Assess the plasma concentration of CsA (valley value) every 2 weeks in the first 8 weeks. If the plasma concentration of CsA reaches 100-150ug/L, continue to maintain the dose. If the plasma concentration of CsA is below the target concentration, increase the dose of CsA. If the plasma concentration of CsA is higher than the upper limit of the target concentration, appropriate dose reduction. A single dose adjustment is 25mg/d. After increasing/decreasing the dose, CsA concentration is remeasured at intervals of 2 weeks ±3 days until the target concentration is reached.~CsA at target concentration followed by 24 weeks of treatment, then the dosage shall be adjusted according to efficacy.
Trial: NCT05674825
Drug: Targeted agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Molecular Tumor Board (MTB) will suggest molecularly targeted matched treatment.
Trial: NCT05674825
Drug: Standard of care agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive treating physician's choice of traditional systemic therapy treatment for their malignancy, defined by National Comprehensive Cancer Network (NCCN) guidelines and/or tumor board recommendation(s).
Trial: NCT05580250
Drug: LY3526318
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05580250
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05580250
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05422001
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic Saline
Trial: NCT06361927
Drug: SSGJ-707
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bispecific antibody
Trial: NCT06265454
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT05157412
Drug: Doxycycline 100 mg Oral Tablet
RxNorm normalized name: DOXYCYCLINE 100 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Doxycycline will be added to prednisolone as a comparison to using prednisolone as a sole therapy for the treatment of nasal polyps associated with chronic rhinosinusitis
Trial: NCT05157412
Drug: Prednisolone 20 mg
RxNorm normalized name: prednisolone 20 MG
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone will be used in both arms as a sole therapy in one and together with doxycycline in the other
Trial: NCT06020911
Drug: Biodentine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 primary second molars of 17 children will be capped with Biodentine
Trial: NCT05059873
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo of 40mg/day for five consecutive days
Trial: NCT05966584
Drug: fulvestrant or AIs) and PI3K inhibition (alpelisib)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC endocrine therapy (fulvestrant or AIs) and PI3K inhibition (alpelisib)
Trial: NCT04009759
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adult patients with an in-hospital cardiac arrest will be evaluated by anaesthesiologists for inclusions criteria to the study and randomised to get the blinded study medicine as addition to standard treatment of cardiac arrest. Randomization will be performed by means of sealed envelopes containing number of syringe that will be used.
Trial: NCT04933383
Drug: AQ001S 0.125 mg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered by nebulization once daily
Trial: NCT05819970
Drug: Allium Sativum Oil
RxNorm normalized name: Allium sativum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allium sativum oil will be used as non-vital pulpotomy medicament
Trial: NCT05524389
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous concurrent or sequential adjuvant chemotherapy consists of carboplatin/paclitaxel, cisplatin/doxorubicin or cisplatin/doxorubicin/paclitaxel, etc.
Trial: NCT05224128
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules (similar appearance with imatinib) without active substance have to be taken orally for 24 weeks in a seated position with a meal or a large (at least 250 mL) glass of water
Trial: NCT05731518
Drug: SC0245
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC0245 Quaque Die(QD) administered with a 3-day on and 4-day off schedule in Day 1 Day8 and Day 15 of each cycle. One cycle is consisted of 28 days.
Trial: NCT05637216
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 25 milligram oral capsule
Trial: NCT05383183
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT06512753
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX (16) is given at a dose of 15 mg per week, orally or subcutaneously. Additionally, folate supplementation is administered concurrently as part of standard care, with folate 10 mg/week administered 24 hours after MTX intake.
Trial: NCT05641298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT04982289
Drug: ALXN1830
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an SC infusion.
Trial: NCT04135092
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
Trial: NCT04583735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT05223400
Drug: Clindamycin Injection
RxNorm normalized name: clindamycin Injection
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: it is a clindamycin use evaluation study
Trial: NCT06301074
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In SAD, participants will be assigned to receive either HS-10509 or a matching placebo for a single administration. There are 5 predefined dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), initially starting at 10 mg for cohort 1.~In MAD, participants will assigned to receive HS-10509 or a matching placebo once daily for 28 days. There will be 3 dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), and the dose for each cohort is to be determined.
Trial: NCT05579431
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension for oral administration.
Trial: NCT05579964
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Priming dose of NaCl 0.9% in a 5 ml syringe mixed in priming fluid and NaCl 0.9% 20 ml in a 20 ml syringe administered to the CPB reservoir with an infusion rate of 10 ml/hour
Trial: NCT06108024
Drug: SM-020 gel 1.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SM-020 gel 1.0% will be applied topically. Subjects will be treated with twice daily application to 5 to 10 SKTLs for approximately 28 days.
Trial: NCT06108024
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle gel will be applied topically. Subjects will be treated with twice daily application to 5 to 10 SKTLs for approximately 28 days.
Trial: NCT05474014
Drug: intravenous patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesics will be given using a patient-controlled analgesia device.
Trial: NCT05435027
Drug: GRT-R912, samRNA-Spikebeta-TCE11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM injection of GRT-R912. Doses will be decided after safety review of Part A.
Trial: NCT05435027
Drug: GRT-R914, samRNA-Spikebeta-TCE9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: 3 microgram (mcg), 10 mcg, or 30 mcg intramuscular (IM) injection of GRT-R914.~Part C: IM injection of GRT-R914. Doses decided after safety review of Part A.
Trial: NCT05435027
Drug: GRT-R918, samRNA-SpikeOmicron-N-TCE11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM injection of GRT-R918. Doses will be decided after safety review of Part A.
Trial: NCT06188715
Drug: Placebo MOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets for moxidectin
Trial: NCT05382208
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg orally twice a day.
Trial: NCT05382208
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo orally twice a day.
Trial: NCT05023915
Drug: diammonium glycyrrhizinate enteric-coated capsule
RxNorm normalized name: glycyrrhizinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg tid for 3 months
Trial: NCT06211309
Drug: co.mouthwas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
Trial: NCT05952102
Drug: Nigella Sativa Oil capsule
RxNorm normalized name: Nigella sativa seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella Sativa Oil as an Adjuvant Therapy in the Treatment of Pediatric Pneumonia
Trial: NCT05774067
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patient received noradrenaline infusion at rate 0.1 mcg/kg/min. with deflation of tourniquet
Trial: NCT03896815
Drug: INCB054329
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04762758
Drug: (RS)-baclofen, naltrexone hydrochloride and D-sorbitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral fixed dose combination
Trial: NCT04762758
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liquid oral solution
Trial: NCT05455697
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05455697
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05152849
Drug: AXA1125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AXA1125 administered BID with or without food
Trial: NCT05152849
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo administered BID with or without food
Trial: NCT06062641
Drug: SR-GDP
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor 40mg/d，po d1,8,15; rituximab 375mg/m2, iv d1; gemcitabine 1g/m2, iv d1,8; cisplatin 25mg/m2, iv d1-3; dexamethasone 40mg，po/iv d1-4 (If patient\>70y, the dosage should be changed to 20mg). Each cycle lasts for 21 days, with a maximum of 6 cycles of combination therapy. For patients who achieved PR or better response at the end of combination therapy, they will start receiving single-agent selinexor 40mg treatment (qw) in cycles of 28 days until disease progression (PD) or unacceptable toxicity occurs.
Trial: NCT05340231
Drug: TACE protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transarterial infusion chemotherapy: Oxaliplatin(85mg/m\^2)+Raltitrexed(3mg) Chemoembolization: Lipiodol emulsion (lipiodol 10ml+ Oxaliplatin 85mg +Lidocaine 1ml)，The endpoint for embolization was defined as stagnation of blood flow of the posterior mesenteric artery.~Intervention cycle：4W; Treatment times: 2. followed by mFOLFOX6
Trial: NCT04877756
Drug: OLX10010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized cake reconstituted with WFI and injected intradermally
Trial: NCT04794218
Drug: rVSV∆G-LASV-GPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 × 10\^5 pfu delivered intramuscularly
Trial: NCT04794218
Drug: rVSV∆G-LASV-GPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 × 10\^6 pfu delivered intramuscularly
Trial: NCT04736485
Drug: perioperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLOT + Spartalizumab
Trial: NCT06053424
Drug: [11C]AZ14132516
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioligand
Trial: NCT06052332
Drug: Adjuvant chemotherapy (optional)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The choice of the adjuvant chemotherapy is to the investigator's discretion.
Trial: NCT04505358
Drug: PU-AD
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: active vs placebo
Trial: NCT04755920
Drug: SGM-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorescence-guided surgery
Trial: NCT04814108
Drug: ZN-c3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZN-c3 is an investigational drug.
Trial: NCT04314375
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo once daily.
Trial: NCT06609187
Drug: GNC-077
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Trial: NCT06699459
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ① Capecitabine, 1250mg/m2 orally, bid, Q3W, d1-14;
Trial: NCT04809623
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match edecesertib tablets administered orally
Trial: NCT05076110
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg three times a day for 2 weeks postoperatively for pain control; not to exceed 3200 mg/day